OBJECTIVE.: To evaluate changes in vascular and musculoskeletal involvement in subjects in the Scleroderma Lung Study (SLS), a multicenter, double-blind, randomized, controlled trial comparing placebo treatment to oral cyclophosphamide for 1 year in systemic sclerosis (SSc) (…)
[Read article]
[Source: NCBI PubMed]
BASEL, SWITZERLAND-(Marketwire - August 27, 2010) - Basilea Pharmaceutica AG / Basilea announces distribution agreement with Actelion for Toctino in Canada processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Basel, (…)
[Read article]
[Source: BioSpace]
Actelion Pharmaceuticals US, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/bf790f/competitor_analysi) has announced the addition of the "Competitor Analysis: Tau and Amyloid Beta Targeted Therapy of Alzheimers Disease" report to their offering. Competitor (…)
[Read article]
[Source: Business Wire]
MedPage Today - Actelion Pharmaceuticals US, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/b5aaab/pharmaceutical_new) has announced the addition of the "Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability 2010" report to their (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/81e154/raising_disease_st) has announced the addition of the "Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products" report to their offering. (…)
[Read article]
[Source: Business Wire]
Macitentan (ACT-064992), under development by Actelion Ltd in collaboration with Japanese licensee Nippon Shinyaku Co Ltd, is an orally active, non-peptide dual endothelin (ET)A and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and (…)
[Read article]
[Source: NCBI PubMed]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/5b2b76/actelion_ltd_phar) has announced the addition of the "Actelion Ltd: PharmaVitae Profile" company profile to their offering. This analysis examines the historical and forecast (…)
[Read article]
[Source: Business Wire]
ET (endothelin)-1 was first described as a potent vasoconstrictor. Since then, many other deleterious properties mediated via its two receptors, ETA and ETB, have been described, such as inflammation, fibrosis and hyperplasia. These effects, combined with a wide tissue (…)
[Read article]
[Source: NCBI PubMed]
Objectives: In this study, the in vitro antimicrobial activity and spectrum of new dimeric compounds derived from the cyanobacterial alkaloid nostocarboline were investigated. The mechanism of action and selectivity to bacteria were studied and compared to the cationic (…)
[Read article]
[Source: NCBI PubMed]
DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Heart Failure research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible (…)
[Read article]
[Source: Business Wire]
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd. Rationale: Multiple sclerosis involves an (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Vascular Diseases research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise (…)
[Read article]
[Source: Business Wire]
Selexipag is an orally available prostacyclin receptor (IP receptor) agonist that is chemically distinct from prostacyclin and is in clinical development for the treatment of pulmonary arterial hypertension. Selexipag is highly selective for the human IP receptor in vitro, (…)
[Read article]
[Source: NCBI PubMed]
DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Heart Disease research database. , based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine tuned by (…)
[Read article]
[Source: Business Wire]
RATIONALE: Orexins play a key role in the maintenance of alertness and are implicated in the modulation of diverse physiological processes, including cognitive function. Almorexant, a dual orexin receptor antagonist, transiently and reversibly blocks the action of orexin (…)
[Read article]
[Source: NCBI PubMed]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/da0ec2/idiopathic_pulmona) has announced the addition of GlobalData 's new report "Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts to 2017" to their offering. (…)
[Read article]
[Source: Business Wire]
21.07.2010 - Actelion Ltd and privately-held Trophos SA announced that they have entered into a binding agreement whereby Actelion has, for EUR 10 million, obtained an exclusive option to acquire privately-held Trophos SA, a clinical stage pharmaceutical company. Trophos' lead (…)
[Read article]
[Source: Bionity.com]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2d2f22/newly_competitive) has announced the addition of Decision Resources, Inc.'s new report "Newly Competitive Gauchers Disease Marketplace: Showcases Strategies for Rare Diseases" to (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/cc5ca4/pharmaceutical_ind) has announced the addition of Decision Resources, Inc.'s new report "Pharmaceutical Industry Dynamics 2010: Licensing Opportunities: Rheumatology" to their (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/19f4ff/alzheimer_disease) has announced the addition of Jain PharmaBiotech's new report "Alzheimer Disease - New Drugs, Markets and Companies" to their offering. Alzheimer Disease - New (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ebb846/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Global Strategic Business Report" report to their offering. Cystic Fibrosis - Global Strategic Business Report (…)
[Read article]
[Source: Business Wire]
CAMBRIDGE, Mass.-(BUSINESS WIRE)-BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing best in class therapeutics based on its proprietary targeted nanotechnology platform, announced today that it has secured a $12.4 Million Series C-1 (…)
[Read article]
[Source: BioSpace]
ChemMedChem. |-| Gatfield J, Brisbare-Roch C, Jenck F, Boss C. |-| Drug Discovery Biology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123 Allschwil/BL (Switzerland).
[Read article]
[Source: NCBI PubMed]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f8d776/global_top_10_biot) has announced the addition of the "Global Top 10 Biotechnology Companies Industry, Financial and SWOT Analysis" report to their offering. Global Top 10 (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/1e827b/new_product_planni) has announced the addition of the "New Product Planning: Role and Activities for Medical Marketing" report to their offering. New Product Planning: Role and (…)
[Read article]
[Source: Business Wire]
BERLIN-(BUSINESS WIRE)-NOXXON Pharma AG (NOXXON), a company focused on the development of mirror image oligonucleotide therapeutics called Spiegelmers, announced today the successful closing of a ¬33 million Series D round of financing. The round was led by new investor, NGN (…)
[Read article]
[Source: BioSpace]
SCOTTSDALE, Ariz.-(BUSINESS WIRE)-The National Council for Prescription Drug Programs (NCPDP) announced today the second consecutive year of record-breaking attendance at its Annual Technology and Business Conference. The 2010 conference garnered the attention of stakeholders (…)
[Read article]
[Source: Business Wire]
NEW ORLEANS, May 17 /PRNewswire-FirstCall/ - Actelion Ltd announced today that findings from the REVEAL (Registry to EValuate Early And Long-term PAH Disease Management) Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/79ddfd/gprotein_coupled) has announced the addition of the "G-Protein Coupled Receptors (GPCRs) - Global Strategic Business Report" report to their offering. G-Protein Coupled Receptors (…)
[Read article]
[Source: Business Wire]
Sphingosine-1-phosphate (S1P) is a widespread lysophospholipid which displays a wealth of biological effects. Extracellular S1P conveys its activity through five specific G-protein coupled receptors numbered S1P(1) through S1P(5). Agonists of the S1P(1) receptor block the (…)
[Read article]
[Source: NCBI PubMed]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c21086/licensing_opportun) has announced the addition of Decision Resources, Inc.'s new report "Licensing Opportunities: Neurology" to their offering. The future of drug discovery and (…)
[Read article]
[Source: Business Wire]
BACKGROUND: We aimed to investigate the extent of pharmacokinetic drug interactions between bosentan and a fixed combination of lopinavir/ritonavir. METHODS: This was a three-way crossover study in 12 healthy male participants treated with bosentan (125 mg twice daily) and (…)
[Read article]
[Source: NCBI PubMed]
Almorexant, a dual orexin receptor antagonist potentially representing a new class of sleep-promoting compounds, was administered in an ascending single-dose study to evaluate tolerability, pharmacokinetics, and pharmacodynamics. Seventy healthy male subjects were enrolled in (…)
[Read article]
[Source: NCBI PubMed]
Endothelins were first identified as potent vasoactive peptides; however, diversity in the biological function of these hormones is now evident. We have identified a novel role for endothelins: a requirement for these peptides within the oviduct during fertilization and/or (…)
[Read article]
[Source: NCBI PubMed]
SOUTH SAN FRANCISCO, Calif. and MEMPHIS, Tenn., April 22 /PRNewswire/ - Actelion Pharmaceuticals US, Inc., today announced that it has selected Accredo Health Group, Inc., a wholly-owned subsidiary of Medco Health Solutions, Inc., to serve as the sole specialty pharmacy (…)
[Read article]
[Source: BioSpace]
SOUTH SAN FRANCISCO, Calif., April 22 /PRNewswire/ - Actelion Pharmaceuticals US, Inc. today announced the commercial availability of Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, for the treatment of primary pulmonary (…)
[Read article]
[Source: BioSpace]
SINGAPORE-(BUSINESS WIRE)-Invida Group, the leading provider of healthcare brands and services to the Asia Pacific region, today announced that its contract with Swiss biotechnology company, Actelion, has been extended through 2015 to continue commercialization of Tracleer (…)
[Read article]
[Source: Business Wire]
SINGAPORE-(BUSINESS WIRE)-Invida Group, the leading provider of healthcare brands and services to the Asia Pacific region, today announced that its contract with Swiss biotechnology company, Actelion, has been extended through 2015 to continue commercialization of Tracleer (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6c4d91/idiopathic_pulmona) has announced the addition of GlobalData 's new report "Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering. (…)
[Read article]
[Source: Business Wire]
LAVAL, CANADA-(Marketwire - March 23, 2010) - Actelion Ltd (SIX:ATLN) announced the approval of a new indication for Zavesca (miglustat) in Canada; the first and only treatment available for people with Niemann-Pick type C (NP-C) disease [1]. NP-C is a rare, genetic disease (…)
[Read article]
[Source: Marketwire]